Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions

This article was originally published in The Tan Sheet

Executive Summary

A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change

You may also be interested in...



Prilosec OTC Patent Extension Submission Pending At PTO

AstraZeneca appears to be building its case to ward off eventual private label competition for Prilosec OTC upon expiration of Hatch/Waxman exclusivity

Prilosec OTC Name Will Create Consumer Confusion With Rx Drugs – Petition

FDA should require that Prilosec OTC be sold under a different brand name to "reduce the risk of consumer confusion" resulting from extensive direct-to-consumer advertising for the Rx version of the drug, an Aug. 12 citizen petition says

Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes

FDA's June 20 approval of Procter & Gamble/ AstraZeneca's Prilosec OTC permits the companies to sell the proton pump inhibitor in packages containing more than one 14-day treatment regimen

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS097854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel